Cargando…
Pharmacokinetics of a Novel Anagrelide Extended‐Release Formulation in Healthy Subjects: Food Intake and Comparison With a Reference Product
Anagrelide is an established therapy for essential thrombocythemia. Common adverse effects have been linked to peak plasma concentrations of anagrelide and its 3OH metabolite. Our study was performed to investigate the pharmacokinetics (PK) of a novel anagrelide extended‐release (AER) formulation an...
Autores principales: | Petrides, Petro E., Schoergenhofer, Christian, Widmann, Rudolf, Jilma, Bernd, Klade, Christoph S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5811889/ https://www.ncbi.nlm.nih.gov/pubmed/28301098 http://dx.doi.org/10.1002/cpdd.340 |
Ejemplares similares
-
Cardiovascular Safety of Anagrelide in Healthy Subjects: Effects of Caffeine and Food Intake on Pharmacokinetics and Adverse Reactions
por: Martínez-Sellés, Manuel, et al.
Publicado: (2012) -
A phase III randomized, multicentre, double blind, active controlled trial to compare the efficacy and safety of two different anagrelide formulations in patients with essential thrombocythaemia – the TEAM‐ET 2·0 trial
por: Gisslinger, Heinz, et al.
Publicado: (2019) -
Comparative steady-state pharmacokinetic study of an extended-release formulation of itopride and its immediate-release reference formulation in healthy volunteers
por: Yoon, Seonghae, et al.
Publicado: (2014) -
Leg Ulcers Associated with Anagrelide
por: Oskay, Tuba, et al.
Publicado: (2021) -
Micellar Curcumin: Pharmacokinetics and Effects on Inflammation Markers and PCSK‐9 Concentrations in Healthy Subjects in a Double‐Blind, Randomized, Active‐Controlled, Crossover Trial
por: Grafeneder, Juergen, et al.
Publicado: (2022)